ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
US – Governor Terry E. Branstad travelled to Sioux Center last week to attend the grand opening for one of three Boehringer Ingelheim Vetmedica, Inc. (BIVI) specialised vaccine research facilities.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
4th Boehringer Ingelheim Expert Forum on Farm-Animal Well-Being
CHINA & GERMANY
Research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical City in Jiangsu Province, China, held a ground-breaking ceremony for a veterinary vaccine manufacturing plant at the China Medical City (Taizhou China Medicine High-Tech Development Zone) last week (Friday, 16 August).
Marta Fornos
Here you can read and download some of the posters presented during ESPHM 2017 in Prague
Get the latest news on Swine Health Subscribe to our newsletter